Englerins A and B are guaiane sesquiterpenes that were isolated from the bark of Phyllanthus engleri, a plant indigenous to east Africa. The englerins consist of a 5-6-5 fused tricyclic structure with an ether bridge and two ester-bearing stereogenic centers, including a highly unusual glycolate residue. Englerin A is a potent and selective inhibitor of the growth of six human renal cancer cell lines. We report herein an efficient, eight-step synthesis of englerin A that leverages simple carbonyl-enabled carbon carbon bond formations. Our route is amenable to the production of a diverse series of analogues for structure function studies and determination of the mode of action of these natural products.
[EN] AZA-EPOXY-GUAIANE DERIVATIVES AND TREATMENT OF CANCER<br/>[FR] DERIVES D'AZA-EPOXY-GUAIANE ET TRAITEMENT DU CANCER
申请人:US HEALTH
公开号:WO2015120140A1
公开(公告)日:2015-08-13
Disclosed is a compound of formula (I) or formula (II): (Formulas should be inserted here) wherein R1-R6 are as defined herein. Also disclosed are a pharmaceutical composition comprising such a compound and a method of treating or preventing cancer in a mammal in need thereof, comprising administering to the mammal a compound of formula (I) or formula (II).
Synthesis of a stable and orally bioavailable englerin analogue
作者:David M. Fash、Cody J. Peer、Zhenwu Li、Ian J. Talisman、Sima Hayavi、Florian J. Sulzmaier、Joe W. Ramos、Carole Sourbier、Leonard Neckers、W. Douglas Figg、John A. Beutler、William J. Chain
DOI:10.1016/j.bmcl.2016.04.016
日期:2016.6
Synthesis of analogues of englerin A with a reduced propensity for hydrolysis of the glycolate moiety led to a compound which possessed the renal cancer cell selectivity of the parent and was orally bioavailable in mice.
Process for the preparation of naphthalen-2-yl-pyrazol-3-one intermediates useful in the synthesis of sigma receptor inhibitors
申请人:Laboratorios Del. Dr. Esteve, S.A.
公开号:EP2112139A1
公开(公告)日:2009-10-28
The invention relates to a process for preparing naphthalen-2-yl-pyrazol-3-one intermediates, tautomers, and salts thereof, to novel intermediates, and to the use of the intermediates in the preparation of sigma receptor inhibitors.